1-3 of 3
Marloes E.C. Broekmans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Christie P.M. Verkleij, Chloe A. O’Neill, Marloes E.C. Broekmans, Kristine A. Frerichs, Wassilis S.C. Bruins, Carolien Duetz, Sandy Kruyswijk, Serena R. Baglio, Sheri Skerget, Rocio Montes de Oca, Sonja Zweegman, Raluca I. Verona, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 3006–3022.
https://doi.org/10.1158/1078-0432.CCR-23-3333
Published: 15 July 2024
View article titled, T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Open the PDF for T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Berris van Kessel, Martijn W. Heymans, Lisa C. Holthof, Christie P.M. Verkleij, Rengasamy Boominathan, Bhavesh Vaidya, Jocelyn Sendecki, Amy Axel, Francois Gaudet, Kodandaram Pillarisetti, Sonja Zweegman, Homer C. Adams, III, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2203–2215.
https://doi.org/10.1158/1078-0432.CCR-19-2299
Published: 01 May 2020
View article titled, Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
Open the PDF for Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab in another window
Includes: Supplementary data
Journal Articles

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7498–7511.
https://doi.org/10.1158/1078-0432.CCR-17-2027
Published: 14 December 2017
View article titled, Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Open the PDF for Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab in another window
Includes: Supplementary data